Last updated on December 2019

A Study Evaluating Safety Pharmacokinetics and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Brief description of study

This first-in-human, open-label, multicenter, Phase Ia/Ib, adaptive, multiple ascending-dose study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of RO6874281 as a single agent (Part A) or in combination with trastuzumab or cetuximab (Part B or C).

Clinical Study Identifier: NCT02627274

Find a site near you

Start Over

UCSD - Moores Cancer Center

La Jolla, CA United States
  Connect »

Memorial Sloan Kettering

New York, NY United States
  Connect »

Erasmus MC

Rotterdam, Netherlands
  Connect »

Leicester Royal Infirmary

Leicester, United Kingdom
  Connect »

Christie Hospital

Manchester, United Kingdom
  Connect »

UZ Antwerpen

Edegem, Belgium
  Connect »

The Ohio State University

Columbus, OH United States
  Connect »